Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.27) by 40.74 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $7.548 million which missed the analyst consensus estimate of $12.267 million by 38.47 percent. This is a 37.25 percent decrease over sales of $12.029 million the same period last year.